Monday 15 May 2023
08:30
Registration
09:00
Opening/Welcome ANR meeting
09:15 - 10:15 Plenary session 1: Genetic defects and dependencies in neuroblastoma
Moderators: Matthias Fischer, Germany & Carol Thiele, United States
09:15
PS1.1 Spontaneous regression and differentiation in neuroblastoma lacking telomerase
Lisa Werr, Germany
09:30
PS1.2 TFIIIC and MYCN link the three-dimensional chromatin structure of promoters to transcription termination of stalled RNA polymerase II
Martin Eilers, Germany
09:45
PS1.3 Inactivating mutations of MKK7 in a subgroup of high-risk neuroblastoma
Anna-Maria Hellman, Germany
10:00
PS1.4 BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma
Kristopher Bosse, United States
10:15
10:15 - 10:45 Coffee break
10:45 - 11:35 Parallel session 1: Genetic defects and dependencies in neuroblastoma
Moderators: Meredith Irwin, Canada & Glenn Marshall, Australia
10:45
O1.1 ATRX alterations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma
Federica Lorenzi, UK
10:57
O1.2 Distinct molecular phenotypes and genetic dependencies within ATRX aberrant neuroblastoma tumors
Marlinde Van Den Boogaard, the Netherlands
11:09
O1.3 DNA Damage Repair Deficiency Enhances Neuroblastoma Progression and In vivo Sensitivity to PARP Inhibition in Zebrafish
Madeline Hayes, Canada
11:21
O1.4 ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation
Marcus Borenäs, Sweden
10:45 - 11:35 Parallel session 2: Treatment strategies for low risk NB
Moderators: Max van Noesel, the Netherlands & Barbara Hero, Germany
10:45
O2.1 Outcomes for patients aged 12-18 months with metastatic MYCN non-amplified neuroblastoma and unfavorable biologic features (‘Mixed Biology Toddlers’)
Thomas Cash, United States
10:57
O2.2 Short term motor outcomes for patients with spinal canal invasion in neuroblastoma – a SIOPEN prospective study
Shifra Ash, Israel
11:09
O2.3 MYCN amplification in INSS stage 1 tumors: is there a need for treatment?
Barbara Hero, Germany
11:21
O2.4 Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Associated with Opsoclonus Myoclonus Ataxia Syndrome (OMAS)
Miriam Rosenberg, Israel
11:35 - 11:50 Rapid Fire session 1A
Moderator: Jan Molenaar, the Netherlands
11:35
P023 Designing Novel Drug Combinations to Improve Sensitivity of ALK-Driven Neuroblastoma Cells to Lorlatinib
Smita Matkar, United States
11:36
P019 High-resolution analysis of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing
Christoph Bartenhagen, Germany
11:37
P022 Genetic predisposition to neuroblastoma results from a regulatory polymorphism promoting the adrenergic cell state in zebrafish and human
Nina Weichert-Leahey, United States
11:38
P018 he druggable target KAT2A forms a feedforward loop with MYCN to drive an oncogenic neuroblastoma transcriptional program
Zhihui Liu, United States
11:39
P021 The chromatin reader PHF6 interacts with RRM2 to control replication stress and DNA damage responses in neuroblastoma
Lisa Depestel, Belgium
11:40
P001 Copper chelation downregulates YTHDF2 RNA-binding protein causing growth inhibition and decreased MYCN expression
Jessica Bell, Australia
11:41
P020 Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
Steffen Fuchs, Germany
11:42
P070 Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance
Adriana Mañas, Sweden
11:43
P075 Palbociclib releases the latent differentiation capacity of neuroblastoma cells
Kirsty Ferguson, UK
11:45
P074 Study of spatial and temporal epigenetic heterogeneity in high-risk neuroblastoma suggests role of H3K27me3-mediated repression
Charlotte Butterworth, France
11:50
11:50 - 13:15 Lunch
Poster viewing P001 - P191
13:15 - 14:00 Keynote Lecture 1
Moderator: Rogier Versteeg, the Netherlands
13:15
Studying melanoma evolution one cell at the time
Chris Marine, Belgium
Although melanoma is notorious for its high degree of heterogeneity and plasticity, the origin and magnitude of cell state diversity remains poorly understood. Equally, it is not known whether melanoma growth and metastatic dissemination and therapy resistance are supported by overlapping or distinct melanoma subpopulations. Leveraging single-cell and spatial transcriptomics, we established a high-resolution and spatially-resolved map of the drug-naïve melanoma ecosystem and a comprehensive view of the malignant transcriptomic landscape. Moreover, by combining mouse genetics, unbiased lineage tracing and quantitative modelling, we provide evidence of a hierarchical model of tumour growth that mirrors the cellular and molecular logic underlying embryonic neural crest cell fate specification and differentiation. Our findings indicate that tumorigenic competence is associated with a spatially localized perivascular niche environment, a phenotype acquired through a NOTCH3-dependent intercellular communication pathway established by endothelial cells. Consistent with a model in which only a fraction of melanoma cells is fated to fuel growth, temporal single-cell tracing of a population of melanoma cells harbouring a mesenchymal-like state revealed that these cells do not contribute to primary tumour growth but, instead, constitutes a pool of metastatic-initiating cells.
We next studied how targeted therapy and immune checkpoint blockade (ICB) remodel the entire melanoma ecosystem. We identified a series of melanoma cell states, and their underlying gene regulatory networks, that are either selected by and/or induced by the treatment to constitute a pool of relapsing-initiating cells. These studies demonstrate that the ability to support growth, metastasis and therapy resistance is limited to partly overlapping pools of melanoma subpopulations. The observation that these phenotypic competencies can be dynamically acquired upon exposure to specific niche signals warrant the development of therapeutic strategies that interfere with the cancer cell reprogramming activity of such microenvironmental cues.
14:00 - 15:00 Plenary session 2: Plasticity in neuroblastoma and normal development
Moderators: Susanne Schlisio, Sweden & Frank Westermann, Germany
14:00
PS2.1 Tracing the dynamics of neuroblastoma transcriptomic states across the metastatic progression with high depth single cell approaches
Céline Delloye-bourgeois, France
14:15
PS2.2 Spatial and single-cell transcriptomics characterize tumor heterogeneity and early stage tumors in mouse neuroblastoma models
Nour El Houda Djerir, France
14:30
PS2.3 Expansion of an early SOX2 positive cell population in germline ALK mutant iPSCs during in vitro differentiation towards sympathoadrenal progenitors
Stéphane Van Haver, Belgium
14:45
PS2.4 Identification, characterization and therapeutic targeting of chemotherapy resistant high-risk neuroblastoma persister cells
Liron Grossmann, Israel
15:00
15:00 - 15:30 Coffee break
15:30 - 16:20 Parallel Session 3: Plasticity in neuroblastoma and normal development
Moderators: Céline Delloye-Bourgeois, France & Isabel Janoueix-Lerosey, France
15:30
O3.1 Single-cell analysis of heterogeneity in a neuroblastoma relapse model in vivo
Ellen Westerhout, the Netherlands
15:42
O3.2 Epigenetically manifested regulatory networks in three major neuroblastoma subtypes
Kai-Oliver Henrich, Germany
15:54
O3.3 Single-cell clonal heterogeneity and cell-state analysis reveals genomic evolution and developmental cell-state transitions in neuroblastoma
Jörg Otte, Sweden
16:06
O3.4 Single-cell RNA sequencing identifies differences between paired samples of primary tumour and bone marrow metastasis
Caroline Hochheuser, the Netherlands
15:30 - 16:20 Parallel Session 4: 'Bioinformatics, clinical data and sample repositories
Moderators: Jan Koster, the Netherlands & Wendy London, United States
15:30
O4.1 Neuroblastoma develops in early fetal development and its evolutionary duration predicts outcome
Verena Körber, Germany
15:42
O4.2 SIOPEN BIOPORTAL: An international registry linked to a virtual biobank for patients with peripheral neuroblastic tumours
Priyanka Devi-marulkar, France
15:54
O4.3 Systematic review of studies identifying clinical and biological markers of poor survival in high-risk neuroblastoma patients at diagnosis: INRG-BORNEO project
Andrea Vilaplana Blanes, Spain
16:06
O4.4 Building a REDCap on FHIR Tool to Abstract Neuroblastoma Data from Electronic Health Records (EHRs): A Proof-of-Concept Study
Brian Furner, United States
16:20
Poster Session Group A
Posters with reference P1 until P110
17:30
Welcome reception
From 17:30 until 19:00 hrs.